Jamie Hirata

2.5k total citations · 1 hit paper
64 papers, 1.4k citations indexed

About

Jamie Hirata is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Jamie Hirata has authored 64 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Pathology and Forensic Medicine, 37 papers in Oncology and 28 papers in Genetics. Recurrent topics in Jamie Hirata's work include Lymphoma Diagnosis and Treatment (55 papers), Chronic Lymphocytic Leukemia Research (28 papers) and CAR-T cell therapy research (18 papers). Jamie Hirata is often cited by papers focused on Lymphoma Diagnosis and Treatment (55 papers), Chronic Lymphocytic Leukemia Research (28 papers) and CAR-T cell therapy research (18 papers). Jamie Hirata collaborates with scholars based in United States, France and Canada. Jamie Hirata's co-authors include Christopher R. Flowers, Andrew McMillan, Laurie H. Sehn, Alex F. Herrera, Matthew J. Matasar, Mark Hertzberg, Muhıt Özcan, Grace Ku, Tae Min Kim and Sarit Assouline and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Jamie Hirata

62 papers receiving 1.4k citations

Hit Papers

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Lar... 2019 2026 2021 2023 2019 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    2019 459 citations Laurie H. Sehn, Alex F. Herrera et al. Journal of Clinical Oncology profile →

Peers

Jamie Hirata
Comparison fields: 5 of 68
  • Pathology and Forensic Medicine 1.1k
  • Oncology 1.0k
  • Genetics 425
  • Radiology, Nuclear Medicine and Imaging 224
  • Immunology 215
Replace Roswitha Forstpointner with:
Roswitha Forstpointner Germany
David Belada Czechia
Andrew Haynes United Kingdom
Clémentine Sarkozy France
Oliver Weigert Germany
Matthew Ku Australia
Celeste Bello United States
Richard H. van der Jagt United States
Timothy J. Murphy United States
Annette Ervin‐Haynes United States
Roswitha Forstpointner Germany View profile →
Citations per field, relative to Jamie Hirata
Jamie Hirata · 1×
Citations per year, relative to Jamie Hirata
Jamie Hirata · 1×

Countries citing papers authored by Jamie Hirata

Since Specialization
Citations

This map shows the geographic impact of Jamie Hirata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jamie Hirata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jamie Hirata more than expected).

Fields of papers citing papers by Jamie Hirata

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jamie Hirata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jamie Hirata. The network helps show where Jamie Hirata may publish in the future.

Co-authorship network of co-authors of Jamie Hirata

This figure shows the co-authorship network connecting the top 25 collaborators of Jamie Hirata. A scholar is included among the top collaborators of Jamie Hirata based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jamie Hirata. Jamie Hirata is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/ TP53 Mutation: SEQUOIA Arm D Results
2025 ·Journal of Clinical Oncology ·Mazyar Shadman, Talha Munir, Shuo Ma, Masa Lasica, Monica Tani, Tadeusz Robak, Ian W. Flinn, Jennifer R. Brown, Paolo Ghia, Emmanuelle Ferrant, Constantine S. Tam, Wojciech Janowski, Wojciech Jurczak, Linlin Xu, Tian Tian, Marcus Lefebure, (unknown), Jamie Hirata, Alessandra Tedeschi
3
2
Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study
2025 ·Blood Advances ·Bei Hu, Patrick M. Reagan, Laurie H. Sehn, Jeff P. Sharman, Mark Hertzberg, Huilai Zhang, Austin I. Kim, Charles Herbaux, Lysiane Molina, Dai Maruyama, Frank Stenner, (unknown), (unknown), Connie Lee Batlevi, Jamie Hirata, Deniz Şahin, Calvin Lee, (unknown), H. Tilly
3
3
Pola-R-CHP or R-CHOEP for first-line therapy of younger patients with high-risk diffuse large B-cell lymphoma: a retrospective comparison of two randomized phase 3 trials
2024 ·Leukemia ·Georg Lenz, Hervé Tilly, Marita Ziepert, Bettina Altmann, Charles Herbaux, (unknown), Maike Nickelsen, Calvin Lee, Jamie Hirata, Deniz Şahin, (unknown), Connie Lee Batlevi, Mark Yan, Franck Morschhauser, Norbert Schmitz
1
4
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: A phase III bridging study in Chinese patients
2024 ·Journal of Cancer Research and Therapeutics ·Yuqin Song, Qingyuan Zhang, (unknown), (unknown), Liling Zhang, Pengcheng He, Li Wang, Jamie Hirata, Lisa Musick, Rong Deng, Wenxin Liu, Xin Wang, (unknown)
1
5
Clinical pharmacology strategies to accelerate the development of polatuzumab vedotin and summary of key findings
2024 ·Advanced Drug Delivery Reviews ·Michael Z. Liao, Dan Lu, Tong Lu, Leonid Gibiansky, Rong Deng, Divya Samineni, Randall Dere, (unknown), Jamie Hirata, Ben‐Quan Shen, Donglu Zhang, Dongwei Li, Chunze Li, Dale Miles
2
6
IMMUNE CONTEXTURE ANALYSIS IN POLARIX SUGGESTS RESPONSE TO POLA‐R‐CHP TREATMENT REDUCES TUMOR MICROENVIRONMENT DEPENDENCY
2023 ·Hematological Oncology ·Franck Morschhauser, Katerina Hatzi, Georg Lenz, Alex F. Herrera, Christopher R. Flowers, Marek Trněný, John M. Burke, Jian Hou, Philipp B. Staber, Eliza A. Hawkes, Koji Izutsu, Steven Le Gouill, David Belada, Alessandra Tucci, (unknown), (unknown), Jamie Hirata, Chengkuo Lee, Yanwen Jiang, Fabrice Jardin
1
7
Ethnic sensitivity assessment: Polatuzumab vedotin pharmacokinetics in Asian and non‐Asian patients with previously untreated diffuse large B‐cell lymphoma in POLARIX
2023 ·Clinical and Translational Science ·Michael Z. Liao, Rong Deng, Leonid Gibiansky, Tong Lü, Priya Agarwal, Randall Dere, Calvin Lee, Jamie Hirata, Charles Herbaux, Gilles Salles, Chunze Li, Dale Miles
3
8
CIRCULATING TUMOR DNA (CTDNA) STATUS AND CLINICAL OUTCOMES IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) IN THE POLARIX STUDY
2023 ·Hematological Oncology ·Alex F. Herrera, Samuel Tracy, Laurie H. Sehn, Fabrice Jardin, Georg Lenz, Marek Trněný, Gilles Salles, (unknown), Hervé Tilly, Jeff P. Sharman, Jonathan W. Friedberg, (unknown), (unknown), Jamie Hirata, Christopher S. Lee, Yizhou Jiang, Franck Morschhauser
1
9
Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study
2023 ·Haematologica ·Christopher R. Flowers, Matthew J. Matasar, Alex F. Herrera, Mark Hertzberg, Sarit Assouline, Judit Demeter, Andrew McMillan, Amitkumar Mehta, Stephen Opat, (unknown), Lisa Musick, Jamie Hirata, Annie Yang, Laurie H. Sehn
4
10
Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study
2022 ·Blood ·Alex F. Herrera, Ronald McCord, Patrick K. Kimes, Fabrice Jardin, Georg Lenz, Marek Trněný, Christopher R. Flowers, Laurie H. Sehn, Gilles Salles, Jeff P. Sharman, Hervé Tilly, Jonathan W. Friedberg, Charles Herbaux, Matthew J. Matasar, Corinne Haïoun, Samuel Tracy, Jamie Hirata, Calvin Lee, Yanwen Jiang, Franck Morschhauser
13
11
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data
2021 ·Blood Advances ·Laurie H. Sehn, Mark Hertzberg, Stephen Opat, Alex F. Herrera, Sarit Assouline, Christopher R. Flowers, Tae Min Kim, Andrew McMillan, Muhıt Özcan, Violaine Safar, Gilles Salles, Grace Ku, Jamie Hirata, Yi Meng Chang, Lisa Musick, Matthew J. Matasar
107
12
Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study
2021 ·The Lancet Haematology ·Catherine Diefenbach, Brad S. Kahl, Andrew McMillan, Javier Briones, (unknown), Raúl Córdoba, Fiona Miall, John M. Burke, Jamie Hirata, Yanwen Jiang, Joseph N. Paulson, Yi Meng Chang, Lisa Musick, Pau Abrisqueta
20
13
POLARGO: Randomized Phase III Study of Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
2021 ·Blood ·Matthew J. Matasar, Corinne Haïoun, Juan‐Manuel Sancho, Andreas Viardot, Jamie Hirata, (unknown), Lisa Musick, Andrew McMillan
4
14
Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study
2020 ·Blood ·Giuseppe Gritti, Paula Marlton, Tycel Phillips, Christopher Arthur, Rajat Bannerji, Paolo Corradini, Anna Johnston, John F. Seymour, (unknown), Jamie Hirata, Lisa Musick, (unknown), (unknown), Christopher R. Flowers
16
15
Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study and Preliminary Results of a Single-Arm Extension
2020 ·Blood ·Laurie H. Sehn, Mark Hertzberg, Stephen Opat, Alex F. Herrera, Sarit Assouline, Christopher R. Flowers, Tae Min Kim, Andrew McMillan, Muhıt Özcan, Violaine Safar, Gilles Salles, Lisa Musick, Jamie Hirata, (unknown), Grace Ku, Matthew J. Matasar
14
16
Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma
2020 ·Pharmaceutical Research ·Dan Lü, Tong Lu, (unknown), Leonid Gibiansky, Priya Agarwal, Colby S. Shemesh, Randall Dere, Uzor C. Ogbu, Jamie Hirata, Pascal Chanu, Sandhya Girish, Jin Y. Jin, Chunze Li, Dale Miles
13
17
Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study
2019 ·The Lancet Oncology ·Hervé Tilly, Franck Morschhauser, Nancy L. Bartlett, Amitkumar Mehta, Gilles Salles, Corinne Haïoun, Javier Muñoz, Andy I. Chen, Kathryn S. Kolibaba, Dan Lü, Mark Yan, Elicia Penuel, Jamie Hirata, Calvin Lee, Jeff P. Sharman
93
18
Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial
2015 ·Blood ·Jennifer R. Brown, Susan O’Brien, (unknown), Herbert Eradat, John M. Pagel, James Lymp, Jamie Hirata, Thomas J. Kipps
57
19
Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices
2012 ·Annals of Oncology ·Ajay K. Nooka, Chadi Nabhan, Xiaolei Zhou, Michael D. Taylor, Michelle Byrtek, Thomas P. Miller, Jonathan W. Friedberg, Andrew D. Zelenetz, Brian K. Link, James R. Cerhan, Hildy Dillon, Rajni Sinha, Pareen J. Shenoy, Deborah M. Levy, Keith Dawson, Jamie Hirata, Christopher R. Flowers
69
20
Characteristics and Effectiveness of Rituximab (R) Maintenance Regimens Among US Patients Diagnosed with Follicular Lymphoma (FL) 2004–2007,
2011 ·Blood ·Loretta J. Nastoupil, Rajni Sinha, Michelle Byrtek, Xiaolei Zhou, Michael Taylor, James R. Cerhan, Jonathan W. Friedberg, Brian K. Link, Jamie Hirata, Christopher R. Flowers
2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Roswitha Forstpointner Breakdown of academic impact, for papers by David Belada Breakdown of academic impact, for papers by Andrew Haynes Breakdown of academic impact, for papers by Clémentine Sarkozy Breakdown of academic impact, for papers by Oliver Weigert Breakdown of academic impact, for papers by Matthew Ku Breakdown of academic impact, for papers by Celeste Bello Breakdown of academic impact, for papers by Richard H. van der Jagt Breakdown of academic impact, for papers by Timothy J. Murphy Breakdown of academic impact, for papers by Annette Ervin‐Haynes
Rankless by CCL
2026